statement
에피노페그듀타이드 2b상 결과는 11/5 AASLD 2026에서 공개됐다.
A statement by 하나증권. Statements are as reported by the cited publishers — not verified by DecisionGateway.
11/5 AASLD 2026 공개
Related claims
에피노페그듀타이드 10mg은 섬유화 개선 외 모든 항목에서 통계적 유의성을 충족했고, 보수적인 mITT 분석에서도 의미 있는 결과를 보였다.하나증권 · statement엘앤에프의 2026년 2분기 실적은 매출 8,850억 원, 영업이익 208억 원, 순이익 529억 원이다.cjdbj · statement엘앤에프의 2026년 1분기 실적은 매출 7,396억 원, 영업이익 1,173억 원, 순이익 -653억 원이다.cjdbj · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statement엘앤에프의 2026년 3분기 영업이익은 예상치 20억 원 대비 1425% 낮다.cjdbj · statement두산의 2026년 3분기 전자BG 매출은 8,020억원(YoY +82%, QoQ +19%), 영업이익 2,353억원(YoY +127%, QoQ +17%, OPM 30%)을 기록했다.하나증권 IT 김민경 · statement
More claims by 하나증권
The report reviewed trends and major economic indicators in the U.S. and Chinese stock markets and analyzed valuations and trends by global sector.statementThe U.S. should watch AI-related regulation and volatility in the semiconductor sector, while for China domestic demand stimulus and policy effects will be key to a sustained rebound.statementThis report is a weekly report covering global sector trends and indicators rather than a single earnings estimate for an individual company, and it does not provide annual aggregate earnings figures.statementAn approach centered on core theme ETFs such as generative AI, semiconductors, quality and cybersecurity, and on major big tech stocks, remains valid.statementAhead of Nvidia's earnings release on 11/18, market attention is focused on Blackwell demand and next-generation GPU supply outlook.statement
All claims by 하나증권